Sol-Gel Technologies Pre-Paid Expenses 2016-2024 | SLGL
Sol-Gel Technologies pre-paid expenses from 2016 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Sol-Gel Technologies Annual Pre-Paid Expenses
(Millions of US $) |
| 2023 |
$3 |
| 2022 |
$2 |
| 2021 |
$1 |
| 2020 |
$1 |
| 2019 |
$1 |
| 2018 |
$3 |
| 2017 |
$2 |
| 2016 |
$1 |
| 2015 |
$0 |
Sol-Gel Technologies Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$1 |
| 2022-06-30 |
$2 |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$1 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$2 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$1 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$1 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$3 |
| 2018-06-30 |
$3 |
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.020B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
